Glycine
Aliases: Glycine · GlyNAC (sa NAC)
Last verified: 2026-09-23
The short version
An amino acid — improves sleep quality (lower core temperature), a glutathione precursor; the GlyNAC combination shows marked metabolic benefits in the elderly. Status: in clinical trials. Legal supplement.
Identity & type
- Molecular type
- mali molekul
- Origin
- An amino acid — improves sleep quality (lower core temperature), a glutathione precursor; the GlyNAC combination shows marked metabolic benefits in the elderly.
Mechanism of action
NMDA/glycine receptors; glutathione synthesis (with NAC); methionine-restriction mimicry.
Dosing & routes
Official / clinical context
No approved official document exists for Glycine. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
3 g before bed (sleep); GlyNAC: ~100 mg/kg/day of each. 3 g before bed: users consistently report deeper sleep and fresher waking; as part of GlyNAC — energy and metabolic effects in the elderly.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
3 g before bed: users consistently report deeper sleep and fresher waking; as part of GlyNAC — energy and metabolic effects in the elderly.
Protocol — official vs community
Official / label
Supplement/amino acid. Sleep studies used 3 g before bed; metabolic studies 3–15 g/day.
- 013 g, 30–60 min before bed (sleep studies)
Duration: Continuous.
The cheapest 'peptide-adjacent' compound in the codex with real human RCT data for sleep onset.
Community (anecdotal)
3 g before bed (sleep) or 10–15 g/day (metabolic/GlyNAC-style protocols).
- Cycle:
- Continuous.
- Break:
- None.
GlyNAC (glycine + NAC) stacks are the community's glutathione-repletion standard.
Human evidence
Sleep RCTs (Ajinomoto); GlyNAC studies (Baylor): improved oxidative stress, glucose, strength.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Very mild.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.